Margin trendWarning
영업이익률 악화 (19.7% → 10.9%, -8.7%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
J2KBIO
420570 · KOSDAQ₩9,440+0.11%
2026-09-04 closeJ2KBIO last closed at ₩9,440 (+0.11%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
Super Strong RS 81 · top 19%
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
A+
Overall: 화학 2/109 · top 1%
Factor composite · relative position in sector
Past reported results · not investment advice
More — deeper indicators
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 1 consecutive years · Raised 0 consecutive years · Yield 2.12% (based on 2025 payment of 200원)
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 12.16
Distress
Grey
Safe
- Altman Z''
- 12.16
- Beneish M-Score
- -3.75
- Sloan accrual
- -23.88%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
5/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score5/9
Profitability
- Positive ROANot passed
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 125% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05화학
This stock is in 화학: revenue rank 99 of 108, share 0%.
99 / 1080%revenue share
Who dominates this industry?
- 1LG화학31.9%
- 2롯데케미칼13.3%
- 3금호석유화학4.7%
- 4DL3.7%
- 5코오롱인더3.2%
- 6제이투케이바이오0%
Concentration
DistributedCR3 49.9%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
MixedConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 8.84
- Direction
- 확대
- Level
- 보통
- Years
- 6
Value lens
- P90/P10
- 9.5
- Median P/B
- 0.68
- Level
- 넓음
- n
- 96
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 10.9%
- Interest coverage
- 37.9x
- Return on equity (ROE)
- -5.3%
Operating margin −5pp
TolerableInterest coverageBase 37.9x adverse case 20.6x
Return on equity (ROE)Base -5.3% adverse case 6%
Revenue −15%
TolerableInterest coverageBase 37.9x adverse case 32.2x
Return on equity (ROE)Base -5.3% adverse case 9.5%
Interest rate +2pp
TolerableInterest coverageBase 37.9x adverse case 19.3x
Return on equity (ROE)Base -5.3% adverse case 11%
Interest coverage limit
Current margin 10.7ppInterest coverage limit at an operating margin of 0.3%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-19Suppliers disclosed by the company in its 2026-03-19 annual report.
Suppliers without disclosed amount
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 이재섭63.27%2024-10-31 · 증감 -2.14%p
Connections
AI-extracted related companies · for reference
Customers
Competitors
Recent filings
J2KBIO's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About J2KBIO
- What technical signals does J2KBIO (420570) have?
- J2KBIO current technical signals: no active technical signal.
- Is J2KBIO a cup-and-handle pattern?
- No. J2KBIO has no valid cup-and-handle signal right now.
- What are J2KBIO's financials and valuation?
- J2KBIO's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy